However, mechanistic understanding of the microenvironmental cues controlling recurrence remains limited due to the absence of suitable preclinical models of ER+ metastatic relapse, with the majority of studies using ER+ human breast cancer cells in immunocompromised mice or ER− mouse mammary tumor cells. This evidence concerns the gene ESR1 and breast carcinoma.